An orally active non-selective endothelin receptor antagonist, bosentan, markedly reduces injury in a rat model of colitis

doi:10.1016/0014-2999(96)00276-2

European Journal of Pharmacology

Volume 309, Issue 3, 15 August 1996, Pages 261-269

https://doi.org/10.1016/0014-2999(96)00276-2 Get rights and content

Abstract

Activation of endothelial cells by vasoactive mediators, such as endothelins, may be an early, strategically important step in the initiation of inflammation in the intestine. In view of recent evidence that inflammatory bowel disease is associated with elevated intestinal concentrations of endothelins and upregulated expression of endothelin receptors on vascular endothelium in intestine, endothelins may become therapeutic targets in inflammatory bowel disease. The recent availability of an orally active, mixed endothelin receptor antagonist, bosentan, allowed us to examine the role of endothelins in a rat model of colitis. Colitis was induced by intra-rectal administration of trinitrobenzene sulphonic acid. In each treatment group, rats were treated with bosentan (10–60 mg/kg p.o.) 24 and 2 h prior to (pre-dose) or 1 h after the induction (post-induction) of colitis and all animals were treated every 24 h thereafter for 5 days. On day 6, stool consistency and the presence of adhesions in the peritoneal cavity were accessed. Colonic tissue samples were removed for determination of macroscopic and microscopic tissue injury, and myeloperoxidase activity. Colitis was typified by tissue ulceration in the distal colon and a corresponding 35-fold increase in myeloperoxidase activity compared to non-inflamed controls. Daily treatment with bosentan dose-dependently reduced colonic damage and myeloperoxidase activity when bosentan was given prior to induction of colitis. In the pre-dose group, the greatest beneficial effect of bosentan was observed at 60 mg/kg; colonic damage and granulocyte infiltration were attenuated by > 80%. A partial therapeutic effect of bosentan was also observed at 60 mg/kg when the pre-treatment regimen was excluded. These findings demonstrate that an orally active, mixed endothelin receptor antagonist has marked protective and therapeutic effects in an animal model of colitis.

References (32)

M.A. Brown et al.
Endothelin: a potent stimulator of intestinal ion secretion in vitro
Reg. Peptides
(1991)
M. Clozel et al.
The endothelin ET_B receptor mediates both vasodilation and vasoconstriction in vivo
Bochem. Biophys. Res. Commun.
(1992)
Y. Hirata et al.
Cellular mechanism of action by a novel vasoconstrictor endothelin in cultured rat vascular smooth muscle cells
Biochem. Biophys. Res. Commun.
(1988)
H. Inagaki et al.
Localization of endothelin-like immunoreactivity and endothelin binding sites in human colon
Gastroenterology
(1991)
T. Kiyohara et al.
Effect of endothelin-1 on ion transport in isolated rat colon
Gastroenterology
(1993)
T. Michida et al.
Role of endothelin-1 in haemorrhagic shock-induced gastric mucosal injury in rats
Gastroenterology
(1994)
R.C. Miller et al.
Endothelins — from receptors to medicine
TIPS
(1993)
G.P. Morris et al.
Hapten-induced model of chronic inflammation and ulceration in the rat colon
Gastroenterology
(1989)
S.H. Murch et al.
High endothelin-1 immunoreactivity in Crohn's disease and ulcerative colitis
Lancet
(1992)
W.C. Sessa et al.
The biosynthesis of endothelin-1 by human polymorphonuclear leucocytes
Bochem. Biophys. Res. Commun.
(1991)

K. Takahashi et al.

Endothelin in the gastrointestinal tract

Presence of endothelin-like immunoreactivity, endothelin-1 mRNA, endothelin receptors and pharmacological effect

Gastroenterology

(1990)

A.J. Wakefield et al.

Granulomatous vasculitis in Crohn's disease

Gastroenterology

(1991)

A.J. Wakefield et al.

Pathogenesis of Crohn's disease: multifocal gastrointestinal infarction

Lancet

(1989)

T. Yamada et al.

A comparative analysis of two models of colitis in rats

Gastroenterology

(1992)

M. Clozel et al.

Pharmacological characterization of bosentan, a new potent orally active non-peptide endothelin receptor antagonist

J. Pharmacol. Exp. Ther.

(1994)

J.G. Filep et al.

Acute pro-inflammatory actions of endothelin-1 in the guinea-pig lung: involvement of ET_A and ET_B receptors

Br. J. Pharmacol.

(1995)

Cited by (30)

Endothelin in human inflammatory bowel disease: Comparison to rat trinitrobenzenesulphonic acid-induced colitis
2002, Life Sciences
There have been suggestions that endothelins (ET-1, ET-2, ET-3) are involved in the pathogenesis of human inflammatory bowel disease (IBD). Furthermore, the non-selective endothelin receptor antagonist, bosentan, ameliorates colonic inflammation in TNBS colitis in rats. However, no studies have measured the tissue expression and release of endothelins in human IBD in direct comparison to experimental TNBS colitis. Mucosal biopsies were obtained from 114 patients (42 Crohn's colitis, 35 ulcerative colitis and 37 normal) and compared to whole colonic segments from rats with TNBS colitis. ET-1/2 levels were reduced in human IBD but greatly increased in experimental TNBS colitis. RT–PCR indicated ET-2 was the predominant endothelin isoform in human IBD whereas ET-1 prevailed in the TNBS model. No associations were found between human IBD and tissue expression, content or release of ET-1/2. Our study shows, therefore, that unlike TNBS colitis in rats, in which ET-1/2 levels are greatly elevated and ET receptor antagonists are efficacious, there is no significant link between endothelins and human IBD.
14 Role of immunohistochemical expression and in situ hybridization expression of endothelin in colon carcinoma
2002, Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas
The growth of malignant tumors depends on neovascularization. Tumor angiogenesis requires angiogenic factors, such as vascular endothelial growth factor (VEGF), provided by cancer cells and affecting the host tissues. The chapter presents a study to determine the precise cellular locations of all components of the endothelins-1 (ETs-1) system in the human normal colon and to gain an insight into the possible role of ET-1 in gastrointestinal physiology. The distributions of prepro-ETs (PPET-1), ET-converting enzyme (ECE) -1, ETA, and ETB receptor mRNAs are studied by in situ hybridization. The cells containing the mRNAs are further examined by comparing the distribution of these mRNAs with the markers of endothelial cells, smooth muscle cells, and macrophages. The chapter compares the expression of mRNAs and proteins of all components of the ET-1 system in the human normal colon, adenoma, and adenocarcinoma colon to assess their potential role in tumor vascularization. It also uses an experimental rat model of colon cancer, with or without bosentan (a mixed antagonist of ETA and ETB receptors) treatment to further evaluate the influence of ET-1 receptors and α-smooth-muscle actin-positive cells in stromal angiogenic responses. In situ hybridization and immunohistochemistry techniques allow a precise localization of the components of the ET system linked to cellular marker in tumor tissue.
The endothelin system in septic and endotoxin shock
2000, European Journal of Pharmacology
The view of the endothelium as a passive barrier has gradually changed as a number of endothelium-derived substances have been discovered. Substances like nitric oxide, prostaglandins and endothelins have potent and important properties, involving not only the circulation as such but also the response to stimuli like inflammation and trauma. The endothelin system, discovered in 1988, has not only strong vasoconstrictor properties, but also immunomodulating, endocrinological and neurological effects exerted through at least two types of receptors. Septic shock, a condition with high mortality, is associated with vast cardiovascular changes, organ dysfunction with microcirculatory disturbances and dysoxia. In the experimental setting, endotoxaemia resembles these changes and is, as well as septic shock, accompanied by a pronounced increase in plasma endothelin levels. The pathophysiology in septic and endotoxin shock remains to be fully elucidated, but several studies indicate that endothelial dysfunction is one contributing mechanism. Activation of the endothelin system is associated with several pathological conditions complicating septic shock, such as acute respiratory distress syndrome, cardiac dysfunction, splanchnic hypoperfusion and disseminated intravascular coagulation. Through the development of both selective and nonselective endothelin receptor antagonists, the endothelin system has been the object of a large number of studies during the last decade. This review highlights systematically the findings of previous studies in the area. It provides strong indications that the endothelin system, apart from being a marker of vascular injury, is directly involved in the pathophysiology of septic and endotoxin shock. Interventions with endothelin receptor antagonists during septic and endotoxin shock have so far only been done in animal studies but the results are interesting and promising.
Endothelins and inflammation: The gastrointestinal system
1999, Pathophysiology
Endothelin (ET) is a very potent vasoconstrictor peptide produced by the vascular endothelium. Several studies have shown that the endothelin system is activated in various inflammatory conditions, including ischemia-reperfusion injury, septic shock, severe traumatic injury, colitis, stress ulcer and peptic ulcer. This article focuses on the role of ET in gastrointestinal inflammation. Particular emphasis is devoted to the contribution of ET to the modulation of gastrointestinal microcirculation and microvascular permeability and leukocyte activation and accumulation. These issues are also addressed in an integrated fashion for the pathologic condition, ischemia-reperfusion (I/R).
The protective effect of bosentan on methotrexate-induced oral mucositis in rats
2023, Iraqi Journal of Veterinary Sciences
Inhibition of mite-induced dermatitis, pruritus, and nerve sprouting in mice by the endothelin receptor antagonist bosentan
2021, Allergy: European Journal of Allergy and Clinical Immunology

View all citing articles on Scopus

View full text

An orally active non-selective endothelin receptor antagonist, bosentan, markedly reduces injury in a rat model of colitis

Abstract

Reg. Peptides

Bochem. Biophys. Res. Commun.

Biochem. Biophys. Res. Commun.

Gastroenterology

Gastroenterology

Gastroenterology

TIPS

Gastroenterology

Lancet

Bochem. Biophys. Res. Commun.

Gastroenterology

Gastroenterology

Lancet

Gastroenterology

Pharmacological characterization of bosentan, a new potent orally active non-peptide endothelin receptor antagonist

J. Pharmacol. Exp. Ther.

Acute pro-inflammatory actions of endothelin-1 in the guinea-pig lung: involvement of ETA and ETB receptors

Br. J. Pharmacol.

Acute pro-inflammatory actions of endothelin-1 in the guinea-pig lung: involvement of ET_A and ET_B receptors